WO2012097518A1 - 治疗痤疮的药 - Google Patents
治疗痤疮的药 Download PDFInfo
- Publication number
- WO2012097518A1 WO2012097518A1 PCT/CN2011/070439 CN2011070439W WO2012097518A1 WO 2012097518 A1 WO2012097518 A1 WO 2012097518A1 CN 2011070439 W CN2011070439 W CN 2011070439W WO 2012097518 A1 WO2012097518 A1 WO 2012097518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- treating acne
- medicament
- acne
- ofloxacin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Definitions
- the present invention relates to a medicament for treating acne.
- a medicine for treating acne characterized in that the pharmaceutical ingredient is composed of the following components by weight:
- the pharmaceutical composition for treating acne is prepared by mixing the following components by weight:
- the invention has excellent therapeutic effect. According to statistics, more than 50 patients who have been treated have a cure rate of 100%, of which 18 In patients with sequelae, the sequelae have been alleviated and disappeared to varying degrees, achieving good results in restoring healthy skin.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
技术领域
本发明涉及一种治疗痤疮的药。
背景技术
现有治疗痤疮的药物很多，但治疗效果一般都不理想，而且也无法消除痤疮产生的疤痕、凹坑、色素沉着等后遗症。
发明内容
本发明的目的在于提供一种治疗痤疮效果好的治疗痤疮的药。
本发明的技术解决方案是：
一种治疗痤疮的药，其特征是：其药物成分由下列重量份的组分混合而成：
硫磺 3~8 份 皮硝 3~8 份
氧氟沙星 0.5~1 份 甲氰咪胍 1~3 份。
所述的治疗痤疮的药，其药物成分由下列重量份的组分混合而成：
硫磺 5 份 皮硝 5 份
氧氟沙星 0.75 份 甲氰咪胍 2 份。
本发明治疗效果优异，据统计，已接受治疗的 50 多名患者，治愈率达 100% ，其中 18
名产生后遗症的患者，其后遗症有不同程度的减轻和消失，达到恢复面肤健康的良好效果。
典型病例：
韩某某，女， 26 岁，江苏南通市人，患者全面部密集丘疹、结节、脓包症状 10
年，经多家医疗机构治疗，用过多种内服、外用药物和自购祛痘、痤疮保健品应用都未取得治疗效果，而且还产生了不同程度的疤痕、凹坑、色素沉着等严重影响面部美容的后遗症。经本发明药物治疗，外涂患处，治疗
2 个月，不但面部痤疮症状全部消失，同时轻度面部凹坑等后遗症也消失。面肤健康得到恢复。
唐某，上海市人，男，全面部严重痤疮症状、囊肿多处，经多家医疗机构治疗，效果不明显，用本发明药物涂患处，
2 个月后消除全面部痤疮的严重症状，终止了后遗症的继续形成，对严重后遗症也有效好转。
下面结合实施例对本发明作进一步说明。
具体实施方式
实施例 1 ：
将下列重量份的药物成分及辅料混合制得治疗痤疮的药：
硫磺 5 份 皮硝 5 份
氧氟沙星 0.75 份 甲氰咪胍 2 份。
纯霜（辅料）100份。
实施例 2 ：
将下列重量份的药物成分及辅料混合制得治疗痤疮的药：
硫磺 3 份 皮硝 7 份
氧氟沙星 1 份 甲氰咪胍 3 份。
凡士林（辅料）90份。
实施例 3 ：
将下列重量份的药物成分及辅料混合制得治疗痤疮的药：
硫磺 8 份 皮硝 3 份
氧氟沙星 0.5 份 甲氰咪胍 1 份。
凡士林（辅料）80份。
Claims (1)
1. 一种治疗痤疮的药，其特征是：其药物成分由下列重量份的组分混合而成：
硫磺 3~8 份 皮硝 3~8 份
氧氟沙星 0.5~1 份 甲氰咪胍 1~3 份。
2. 根据权利要求 1 所述的治疗痤疮的药，其特征是：其药物成分由下列重量份的组分混合而成：
硫磺 5 份 皮硝 5 份
氧氟沙星 0.75 份 甲氰咪胍 2 份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/070439 WO2012097518A1 (zh) | 2011-01-20 | 2011-01-20 | 治疗痤疮的药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/070439 WO2012097518A1 (zh) | 2011-01-20 | 2011-01-20 | 治疗痤疮的药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012097518A1 true WO2012097518A1 (zh) | 2012-07-26 |
Family
ID=46515097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2011/070439 WO2012097518A1 (zh) | 2011-01-20 | 2011-01-20 | 治疗痤疮的药 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012097518A1 (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1099260A (zh) * | 1993-08-26 | 1995-03-01 | 耿传芝 | 除痘增白晚霜的制做方法及产品 |
| CN101049315A (zh) * | 2006-04-05 | 2007-10-10 | 马学荣 | 一种寻常痤疮药配方 |
-
2011
- 2011-01-20 WO PCT/CN2011/070439 patent/WO2012097518A1/zh active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1099260A (zh) * | 1993-08-26 | 1995-03-01 | 耿传芝 | 除痘增白晚霜的制做方法及产品 |
| CN101049315A (zh) * | 2006-04-05 | 2007-10-10 | 马学荣 | 一种寻常痤疮药配方 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Rosacea management: a comprehensive review | |
| EP3548058B1 (en) | Compositions comprising peptide wkdeagkplvk | |
| TWI342773B (zh) | ||
| WO2016141219A1 (en) | Strontium based compositions and formulations for pain, pruritus, and inflammation | |
| Bharti et al. | Mesotherapy with botulinum toxin for the treatment of refractory vascular and papulopustular rosacea | |
| JP2017533972A5 (zh) | ||
| JP2021073234A (ja) | 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料 | |
| KR20140012651A (ko) | 파라벤 조성물 | |
| JP2020023558A (ja) | ノカルダミンの新規金属錯体および医薬組成物におけるそれらの使用 | |
| IL269182B1 (en) | Methods for the treatment and/or prevention of actinic radiation | |
| US20170183386A1 (en) | Peptides, and uses thereof | |
| US20110212161A1 (en) | Treatment skin disorders | |
| KR20140027122A (ko) | 피부 질환을 치료하는 방법 | |
| WO2012097518A1 (zh) | 治疗痤疮的药 | |
| JP2012525358A5 (zh) | ||
| WO2003061676A1 (en) | Compositions for and method of treatment for skin ailments | |
| MX2018013477A (es) | Acidos carboxilicos para tratar/prevenir una enfermedad de la piel. | |
| JP2018052836A (ja) | 外用組成物 | |
| EP2712613B1 (en) | Vitamin K1 and uses thereof | |
| JPH03227921A (ja) | ケロイド治療剤 | |
| KR20210066532A (ko) | 페룰산 및 이의 유사체를 포함하는 유전자 돌연변이에 의한 피부질환 예방 및 치료용 조성물 | |
| KR101548254B1 (ko) | 유황, 명반 및 식초를 유효성분으로 포함하는 피부 질환 치료용 조성물 | |
| JPH10265365A (ja) | ニキビ用皮膚外用剤 | |
| US10583081B1 (en) | Apparatus and formulation for treating mouth ulcers | |
| MX2023009424A (es) | Composicion antitranspirante. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11856371 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11856371 Country of ref document: EP Kind code of ref document: A1 |